228
Participants
Start Date
May 7, 2018
Primary Completion Date
February 22, 2023
Study Completion Date
February 22, 2023
APG101
weekly i.v.
Alectinib
twice daily (oral)
Idasanutlin
orally on 5 days of a 28 days cycle
Atezolizumab
i.v. every 3 weeks
Vismodegib
daily orally
Temsirolimus
weekly i.v.
Palbociclib
orally on 21 days of a 28 days cycle
Charité Berlin, Neurosurgery, Berlin
Knappschaftskrankenhaus Bochum GmbH, Neurology Clinic, Bochum
University Hospital Bonn, Neurology Clinic, Bonn
University Hospital Cologne, Neurosurgery, Cologne
University Hospital Dresden, Neurosurgery, Dresden
University Hospital Essen, Neurology Clinic, Essen
University Hospital Frankfurt, Neurooncology, Frankfurt am Main
University Hospital Heidelberg, Neurology Clinic, Heidelberg
University Hospital Saarland, Neurosurgery, Homburg
University Hospital Mainz, Neurosurgery, Mainz
University Hospital Mannheim, Neurology Clinic, Mannheim
University Hospital Regensburg, Neurology Clinic, Regensburg
University Hospital Tuebingen, Neurooncology, Tübingen
German Cancer Aid
OTHER
German Cancer Research Center
OTHER
National Center for Tumor Diseases, Heidelberg
OTHER
University Hospital Heidelberg
OTHER